The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.64 billion (USD 10.8 million1) in four projects for the development of new drugs for malaria and neglected tropical diseases (NTDs).2
Read More – Chamlion Unveils Advanced Dental 3D Printing Solutions At IDEX 2024 Exhibition
The GHIT Fund invests in the development of new drugs, vaccines, and diagnostics for neglected infectious diseases such as malaria, tuberculosis, and NTDs, which predominantly affect the world’s vulnerable and underserved populations. These R&D projects must involve partnerships between Japanese and non-Japanese organizations, and the four new projects consist of diverse partnerships including Japanese pharmaceutical companies and universities, as well as non-Japanese research institutions and universities.
The GHIT Fund will invest approximately JPY 444 million (USD 2.9 million1) in two malaria projects: the development of malaria chemoprevention drug through a partnership among Shionogi & Co., Ltd., Nagasaki University, National Institute of Infectious Diseases, and Medicines for Malaria Venture (MMV), and therapeutic drug development led by Eisai Co., Ltd., the Scripps Research Institute, and International Centre for Genetic Engineering and Biotechnology (ICGEB).
For NTDs, the GHIT Fund will also invest approximately JPY 1.2 billion (USD 7.9 million1) in two projects: drug development for onchocerciasis and lymphatic filariasis led by Eisai Co., Ltd., University Hospital Bonn, and Helmholtz Centre for Infection Research, and the development of a treatment for Chagas disease led by Mitsubishi Tanabe Pharma Corporation and Drugs for Neglected Diseases initiative (DNDi).
Read More – Five Reasons For Hair Loss
The GHIT Fund plays a catalytic role in matching Japanese and global partners to accelerate R&D resulting in the support of over 180 development partners since 2013. Through global partnerships, the GHIT Fund aims to promote open innovation in R&D and create an environment that enables the rapid delivery of products to patients in need.
Please refer to Appendix 1 for a detailed description of each project and its development stage.
As of March 31, 2024, the GHIT Fund invested in 36 projects, including 12 discovery projects, 16 preclinical projects, and 8 clinical trials3 in the portfolio. The total amount of investments since 2013 is JPY 33.2 billion (USD 219 million) (Appendix 2).
1 USD1 = JPY151.33, the approximate exchange rate on March 31, 2024.
2 These awarded projects were selected and approved as new investments from among proposals to RFP2023-001 for the Product Development Platform, which was open for applications from November 2022 to July 2023.
3 This number includes projects in the registration phase.
Read More – Global Heart Hub’s Real-Life Data Highlights Need For Patient-Centered Management Of Unhealthy Cholesterol
The GHIT Fund is a Japan-based international public-private partnership (PPP) fund that was formed between the Government of Japan, multiple pharmaceutical companies, the Bill & Melinda Gates Foundation, Wellcome, and the United Nations Development Programme (UNDP). The GHIT Fund invests in and manages an R&D portfolio of development partnerships aimed at addressing neglected diseases, such as malaria, tuberculosis, and neglected tropical diseases, which afflict the world’s vulnerable and underserved populations. In collaboration with global partners, the GHIT Fund mobilizes Japanese industry, academia, and research institutes to create new drugs, vaccines, and diagnostics for malaria, tuberculosis, and neglected tropical diseases.
Read More – Tri-Tech Expands Emergency Medical Offering With The Strategic Acquisition Of SAM Medical
